Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | FGF2 | P09038 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7408859 | 0.96 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2HPGDHTTMEN1 | |
| SCHEMBL7408862 | 0.88 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2HPGDHTTMEN1 | |
| SCHEMBL7461005 | 0.83 | LCK (0.43) | ALDH1A1SMN1; SMN2HPGDHTTMEN1 | |
| SCHEMBL7460994 | 0.83 | LCK (0.43) | ALDH1A1SMN1; SMN2HPGDHTTMEN1 | |
| SCHEMBL7461000 | 0.83 | LCK (0.43) | ALDH1A1SMN1; SMN2HPGDHTTMEN1 | |
| SCHEMBL7077722 | 0.80 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2HPGDHTTMEN1 | |
| SCHEMBL18020565 | 0.77 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2HPGDHTTMEN1 | |
| SCHEMBL7461692 | 0.77 | SMN1; SMN2 (0.35) | ALDH1A1SMN1; SMN2HPGDHTTMEN1 | |
| SCHEMBL30088682 | 0.77 | SMN1; SMN2 (0.37) | ALDH1A1SMN1; SMN2HPGDHTTMEN1 | |
| SCHEMBL7461694 | 0.77 | SMN1; SMN2 (0.35) | ALDH1A1SMN1; SMN2HPGDHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | OWEN DAVID ALAN (GB) | 2003-11-06 | — | — | US | disclosed |
| US-6566384-B1 | For therapy of cancer, inflammation and inflammatory diseases, tissue degeneration, periodontal disease, ophthalmological disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response | DARWIN DISCOVERY LTD. (GB) | 2003-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | MMP13, MMP2, MMP9 | ALDH1A1 408/4885SMN1; SMN2 3038/4885HPGD 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.